Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume

2014 ◽  
Vol 34 (10) ◽  
pp. 1578-1583 ◽  
Author(s):  
Titus F. M. Wijnands ◽  
Myrte K. Neijenhuis ◽  
Wietske Kievit ◽  
Frederik Nevens ◽  
Marie C. Hogan ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Liver Disease ◽  
Liver Volume ◽  
Polycystic Liver Disease ◽  
Health Related Quality ◽  
Polycystic Liver ◽  
Related Quality ◽  
Health Related ◽  
The Impact

FRI-365-Efficacy of combined partial hepatectomy and cyst fenestration on health-related quality of life in polycystic liver disease

2019 ◽  
Vol 70 (1) ◽  
pp. e555-e556
Author(s):  
Lucas H.P. Bernts ◽  
Myrte Neijenhuis ◽  
Marie E. Edwards ◽  
Rory L. Smoot ◽  
David M. Nagorney ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Liver Disease ◽  
Partial Hepatectomy ◽  
Polycystic Liver Disease ◽  
Health Related Quality ◽  
Polycystic Liver ◽  
Related Quality ◽  
Health Related ◽  
Cyst Fenestration

Health-related quality of life in chronic liver disease: the impact of type and severity of disease

2001 ◽  
Vol 96 (7) ◽  
pp. 2199-2205 ◽  
Author(s):  
Zobair M Younossi ◽  
Navdeep Boparai ◽  
Lori Lyn Price ◽  
Michelle L Kiwi ◽  
Marilyn McCormick ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Chronic Liver ◽  
Health Related Quality ◽  
Severity Of Disease ◽  
Related Quality ◽  
Health Related ◽  
The Impact

scholarly journals Medical therapy for polycystic liver disease

2016 ◽  
Vol 98 (1) ◽  
pp. 18-23 ◽  
Author(s):  
S Khan ◽  
A Dennison ◽  
G Garcea
Keyword(s):  
Quality Of Life ◽  
Liver Disease ◽  
Liver Volume ◽  
Somatostatin Analogues ◽  
Cochrane Library ◽  
Polycystic Liver Disease ◽  
Randomised Trials ◽  
Polycystic Liver ◽  
The Impact

Introduction Somatostatin analogues and rapamycin inhibitors are two classes of drugs available for the management of polycystic liver disease but their overall impact is not clearly established. This article systematically reviews the literature on the medical management of polycystic liver disease. The outcomes assessed include reduction in liver volume and the impact on quality of life. Methods The English language literature published between 1966 and August 2014 was reviewed from a MEDLINE®, PubMed, Embase™ and Cochrane Library search. Search terms included ‘polycystic’, ‘liver’, ‘sirolimus’, ‘everolimus’, ‘PCLD’, ‘somatostatin’, ‘octreotide’, ‘lanreotide’ and ‘rapamycin’. Both randomised trials and controlled studies were included. References of the articles retrieved were also searched to identify any further eligible publications. The studies included were appraised using the Jadad score. Results Seven studies were included in the final review. Five studies, of which three were randomised trials, investigated the role of somatostatin analogues and the results showed a mean reduction in liver volume ranging from 2.9% at six months to 4.95 ±6.77% at one year. Only one randomised study examined the influence of rapamycin inhibitors. This trial compared dual therapy with everolimus and octreotide versus octreotide monotherapy. Liver volume reduced by 3.5% and 3.8% in the control and intervention groups respectively but no statistical difference was found between the two groups (p=0.73). Two randomised trials investigating somatostatin analogues assessed quality of life using SF-36®. Only one subdomain score improved in one of the trials while two subdomain scores improved in the other with somatostatin analogue therapy. Conclusions Somatostatin analogues significantly reduce liver volumes after six months of therapy but have only a modest improvement on quality of life. Rapamycin inhibitors do not confer any additional advantage.

scholarly journals Impact of liver volume on polycystic liver disease-related symptoms and quality of life

2017 ◽  
Vol 6 (1) ◽  
pp. 81-88 ◽  
Author(s):  
Myrte K Neijenhuis ◽  
Wietske Kievit ◽  
Stef MH Verheesen ◽  
Hedwig M D’Agnolo ◽  
Tom JG Gevers ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Liver Disease ◽  
Liver Volume ◽  
Symptom Burden ◽  
Symptom Assessment ◽  
Polycystic Liver Disease ◽  
Polycystic Liver ◽  
Disease Stages ◽  
The Impact

Background Symptoms in polycystic liver disease (PLD) are thought to be caused by compression of organs and structures by the enlarged liver. Aim The aim of this article is to assess the impact of liver volume on symptoms and quality of life (QoL) in PLD. Methods We included PLD patients from two prospective studies that used the PLD-questionnaire (PLD-Q) for symptom assessment. QoL was assessed through SF-36, summarized in a physical (PCS) and mental (MCS) component score. Liver volume was correlated with PLD-Q total scores. Patients were classified based on height-corrected liver volume in mild (<1600 ml), moderate (1600–3200 ml), and severe (>3200 ml) disease. PLD-Q and QoL (PCS and MCS) scores were compared across disease stages. Results We included 82 of 131 patients from the original studies (disease stages; mild n = 26, moderate n = 33, and severe n = 23). Patients with larger liver volume reported higher symptom burden ( r = 0.516, p < 0.001). Symptom scores increased with disease progression, except for abdominal pain ( p = 0.088). PCS decreased with advancing disease ( p < 0.001), in contrast to MCS ( p = 0.055). Moderate ( p = 0.007) and severe ( p < 0.001) PLD patients had lower PCS scores than the general population. Conclusion PLD with larger liver volume is more likely to be symptomatic and is associated with lower QoL.

scholarly journals The Impact of Liver Cell Injury on Health-Related Quality of Life in Patients with Chronic Liver Disease

PLoS ONE ◽  
2016 ◽  
Vol 11 (3) ◽  
pp. e0151200 ◽  
Author(s):  
Yvonne Alt ◽  
Anna Grimm ◽  
Liesa Schlegel ◽  
Annette Grambihler ◽  
Jens M. Kittner ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Liver Disease ◽  
Liver Cell ◽  
Cell Injury ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
Liver Cell Injury ◽  
The Impact

scholarly journals Health-related quality of life in patients with autoimmune hepatitis

2021 ◽  
Author(s):  
Maurice Michel ◽  
Francesca Spinelli ◽  
Annette Grambihler ◽  
Christian Labenz ◽  
Michael Nagel ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Liver Disease ◽  
Autoimmune Hepatitis ◽  
Multivariable Analysis ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
Biochemical Remission ◽  
The Impact

Abstract Background Autoimmune hepatitis (AIH) is a rare chronic liver disease. Impaired health-related quality of life (HRQL) contributes to the overall disease burden. At current, only limited data related to the impact of treatment response on HRQL are available. Objective The aim of the study was to determine the impact of biochemical remission on HRQL. Methods Patients with AIH were prospectively enrolled between July 2018 and June 2019. A liver disease-specific tool, the chronic liver disease questionnaire (CLDQ) and the generic EQ-5D-5L were used to quantify HRQL. Treatment response was assessed biochemically by measurement of immunoglobulin G, ALT and AST. The cohort was divided into two groups according to their biochemical remission status in either complete vs. incomplete remission. Clinical as well as laboratory parameters and comorbidities were analysed using univariable and multivariable analysis to identify predictors of poor HRQL. Results A total of 116 AIH patients were included (median age: 55; 77.6% female), of which 9.5% had liver cirrhosis. In this cohort, 38 (38.4%) showed a complete and 61 (61.6%) an incomplete biochemical remission at study entry. The HRQL was significantly higher in patients with a complete as compared to an incomplete biochemical remission (CLDQ overall score: 5.66 ± 1.15 vs. 5.10 ± 1.35; p = 0.03). In contrast, the generic EQ-5D-5L UI-value was not different between the groups. Multivariable analysis identified AST (p = 0.02) and an incomplete biochemical remission (p = 0.04) as independent predictors of reduced HRQL (CLDQ total value). Conclusion Patients with a complete biochemical remission had a significantly higher HRQL. Liver-related quality of life in patients living with AIH is dependent on the response to immunosuppressive treatment.

ACCESSIBLE HOUSING AND HEALTH-RELATED QUALITY OF LIFE: MEASUREMENTS OF WELLBEING OUTCOMES FOLLOWING HOME MODIFICATIONS

2016 ◽  
Vol 10 (2) ◽  
pp. 38 ◽  
Author(s):  
Phillippa Carnemolla ◽  
Catherine Bridge
Keyword(s):  
Quality Of Life ◽  
Mixed Method ◽  
Exploratory Research ◽  
Health Related Quality ◽  
Care Giving ◽  
Home Modifications ◽  
Related Quality ◽  
Health Related ◽  
The Impact

The multi-dimensional relationship between housing and population health is now well recognised internationally, across both developing and developed nations. This paper examines a dimension within the housing and health relationship – accessibility – that to date has been considered difficult to measure. This paper reports on the mixed method results of larger mixed-method, exploratory study designed to measure the impact of home modifications on Health-Related Quality of Life, supported by qualitative data of recipients’ experiences of home modifications. Data was gathered from 157 Australian HACC clients, who had received home modifications. Measurements were taken for both before and after home modifications and reveal that home modifications were associated with an average 40% increase in Health-Related Quality of Life levels. The qualitative results revealed that participants positively associated home modifications across six effect themes: increased safety and confidence, improved mobility at home, increased independence, supported care-giving role, increased social participation, and ability to return home from hospital. This exploratory research gives an insight into the potential for accessible architecture to impact improvements in community health and wellbeing.

Sign in / Sign up

Export Citation Format

Share Document